microRNA expression is able to predict response to chemoradiotherapy in rectal cancer

Hotchi,Masanori; Shimada,Mitsuo; Kurita,Nobuhiro; Iwata,Takashi; Sato,Hirohiko; Morimoto,Shinya; Yoshikawa,Kozo; Higashijima,Jun; Miyatani,Tomohiko

doi:10.3892/mco.2012.9

microRNA expression is able to predict response to chemoradiotherapy in rectal cancer

Authors:
- Masanori Hotchi
- Mitsuo Shimada
- Nobuhiro Kurita
- Takashi Iwata
- Hirohiko Sato
- Shinya Morimoto
- Kozo Yoshikawa
- Jun Higashijima
- Tomohiko Miyatani
View Affiliations

Affiliations: Department of Surgery, Ehime Prefectural Central Hospital, Matsuyama 790-0024, Japan, Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima 770-8503, Japan
Published online on: August 9, 2012 https://doi.org/10.3892/mco.2012.9
Pages: 137-142

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although global microRNA (miRNA) expression patterns of several embryologic, physiological and oncogenic processes have been thoroughly studied, no studies are available on the role of miRNAs in pre-operative chemoradiotherapy (CRT) in rectal cancer. This study aimed to delineate the expression pattern of miRNAs for the prediction of response to CRT in rectal cancer. Rectal cancer patients (n=43), who underwent pre-operative CRT (40 Gy radiotherapy combined with S-1), were studied. RNA harvested from rectal cancer biopsy specimens prior to pre-operative CRT was hybridized to miRNA microarrays (821 genes). The response to CRT was evaluated by histopathological examination of surgically resected specimens, Response Evaluation Criteria in Solid Tumors (RECIST) and downstaging. The data of miRNA microarray were evaluated by real-time reverse transcription‑polymerase chain reaction (RT-PCR). Two miRNAs (miR-142-3p, 223) with an increased expression that correctly differentiated responders from non-responders to CRT were identified by histopathological examination. One gene (miR‑223) showed a higher, while 8 genes (miR-20b, miR-92a, let-7a*, miR-20a, miR-17*, miR‑106a, miR-17 and miR-20a*) a lower expression in responders compared to non-responders, with regard to RECIST. The 3 genes (miR-223, miR-630 and miR-126*) had a higher expression in responders compared to non-responders, with regard to downstaging. The real-time RT-PCR evaluation analysis detected a higher miR-223 level in responders compared to non-responders. Consequently, candidate miR-223 may be a new biomarker for the prediction of response to CRT and may be useful when establishing tailor-made therapies for rectal cancer.

View Figures

View References

1.	Holm T, Cedermark B and Rutqvist LE: Local recurrence of rectal adenocarcinoma after ‘curative’ surgery with and without pre-operative radiotherapy. Br J Surg. 81:452–455. 1994.
2.	Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H and Raab R; German Rectal Cancer Study Group: Pre-operative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 351:1731–1740. 2004.
3.	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004.
4.	Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005.
5.	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005.
6.	Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B and Rigoutsos I: A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell. 126:1203–1217. 2006.
7.	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006.
8.	Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 25:6188–6196. 2006.
9.	Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D and Slack FJ: The let-7 micro-RNA represses cell proliferation pathways in human cells. Cancer Res. 67:7713–7722. 2007.
10.	Miska EA: How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 15:563–568. 2005.
11.	Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26:293–300. 2007.
12.	Yu SL, Chen HY, Yang PC and Chen JJ: Unique microRNA signature and clinical outcome of cancers. DNA Cell Biol. 26:283–292. 2007.
13.	Japanese Society for Cancer of the Colon and Rectum: Response Assessment of Nonsurgical Treatment for Colorectal Carcinoma. Japanese classification of colorectal carcinoma. 1st English edition. Kanehara & Co. Ltd.; Tokyo: pp. 77–82. 1997
14.	Aslam MI, Taylor K, Pringle JH and Jameson JS: MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg. 96:702–710. 2009.
15.	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC and Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
16.	Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez A, Balagué O and Garcia-Foncillas J: Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res. 18:823–833. 2008.
17.	Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436. 2008.
18.	Svoboda M, Izakovicova Holla L, Sefr R, Vrtkova I, Kocakova I, Tichy B and Dvorak J: Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol. 33:541–547. 2008.
19.	Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E and Slack FJ: MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 67:11111–11116. 2007.
20.	Josson S, Sung SY, Lao K, Chung LW and Johnstone PA: Radiation modulation of microRNA in prostate cancer cell lines. Prostate. 68:1599–1606. 2008.
21.	Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008.
22.	Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR and Potti A: An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One. 3:e19082008.
23.	Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genom Proteom. 3:317–324. 2006.
24.	Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C and Bozzoni I: A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 23:819–831. 2005.
25.	Sugatani T and Hruska KA: MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem. 101:996–999. 2007.
26.	Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y, Kawamura A, Nakamura K, Takeuchi T and Tanabe M: An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell. 129:617–631. 2007.
27.	Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF and Wong N: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 135:257–269. 2008.
28.	Melhem RF, Strahler JR, Hailat N, Zhu XX and Hanash SM: Involvement of OP18 in cell proliferation. Biochem Biophys Res Commun. 179:1649–1655. 1991.
29.	Rubin CL and Atweh GF: The role of stathmin in the regulation of the cell cycle. J Cell Biochem. 93:242–250. 2004.
30.	Brattsand G, Roos G, Marklund U, Ueda H, Landberg G, Nånberg E, Sideras P and Gullberg M: Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in healthy and neoplastic cells. Leukemia. 7:569–579. 1993.
31.	Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS and Kasper S: Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate. 67:1038–1052. 2007.
32.	Alli E, Yang JM, Ford JM and Hait WN: Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 71:1233–1240. 2007.
33.	Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A and Parsons R: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA. 104:7564–7569. 2007.
34.	Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD and Camargo FD: Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 451:1125–1129. 2008.
35.	Guo R, Wu Q, Liu F and Wang Y: Description of the CD133⁺ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep. 25:141–146. 2011.